What is aleniglipron?

What makes aleniglipron different from other oral GLP-1s

Two oral GLP-1 drugs for weight loss are on the market today: the Wegovy pill (oral semaglutide) and orforglipron (Foundayo). Both activate the GLP-1 receptor, but they reach it through very different chemistry.

Oral semaglutide is a peptide. Peptides break down in the stomach, so Novo Nordisk engineered a special carrier molecule to protect it during digestion. That system works, but it demands a fasting window: take the pill with four ounces of water, then wait 30 minutes before eating, drinking, or taking other medications. Skip the window and absorption drops significantly.

Orforglipron and aleniglipron are small molecules, not peptides. Synthetic small-molecule compounds that bind the GLP-1 receptor survive the digestive system without special formulation. No fasting window. No complicated morning routine. Take it with food or without.

The difference between the two small molecules: orforglipron comes from Eli Lilly and received FDA approval in April 2026. Aleniglipron comes from Structure Therapeutics, a smaller biotech, and is still in Phase 2. But the Phase 2 numbers are getting serious attention from researchers and investors alike. For a broader look at how the oral GLP-1 category took shape, see the oral GLP-1 pill guide.

What the Phase 2b ACCESS trial found

The ACCESS trial enrolled 230 adults with obesity (BMI 30 or above) or overweight with at least one weight-related health condition. Participants took once-daily aleniglipron at 45mg, 90mg, or 120mg, or placebo, over 36 weeks. Doses stepped up every four weeks.

Results were published in Nature Medicine on June 5, 2026. At the highest dose, the trial cleared its primary endpoint with a placebo-adjusted weight reduction of 11.3%. That is the weight lost beyond what the placebo group achieved.

Secondary markers improved across the board. Systolic blood pressure dropped 7.5 mmHg more than placebo. HbA1c fell 0.37 percentage points more. Inflammatory marker hsCRP dropped 46%. These are the downstream benefits that make GLP-1 drugs clinically useful beyond weight numbers alone.

Side effects followed the GLP-1 class pattern: mostly nausea, vomiting, and GI discomfort, predominantly mild to moderate. No off-target safety events appeared. Starting at a lower 2.5mg dose in the open-label extension eliminated vomiting and cut discontinuations further, which informs how the Phase 3 titration schedule is likely to be designed.

ACCESS II: what higher doses showed

Structure Therapeutics ran a second Phase 2 study with higher doses over a longer window. In March 2026, the company announced topline results from ACCESS II: at 180mg, aleniglipron produced 16.3% placebo-adjusted weight loss at 44 weeks.

The weight loss curve had not flattened by week 44. Participants were still losing weight at the trial endpoint. Open-label extension data from those who continued past the core study showed total body weight loss reaching 16.2%.

Structure Therapeutics described this as the highest efficacy among oral GLP-1 drugs at the 44-week mark. The qualification matters: ACCESS II was a Phase 2 trial, smaller and shorter than the Phase 3 trials that establish regulatory efficacy. Phase 3 results can land differently. The company is planning to find out, with Phase 3 targeted to start in Q3 2026.

How it compares to approved oral GLP-1s

Three data points for context, keeping in mind Phase 2 and Phase 3 figures are not directly comparable across different studies and populations:

If aleniglipron Phase 3 data lands near what Phase 2 showed, it would be the most effective oral GLP-1 that does not require fasting. That is the scenario the trial data points toward. It is not the scenario confirmed by a Phase 3 trial yet. For a side-by-side breakdown of the two approved oral options, see oral semaglutide vs orforglipron. For a full comparison of the injectable options on the market today, see semaglutide vs tirzepatide.

Why the fasting-free design matters for real-world use

Adherence is the problem no clinical trial captures cleanly. A drug that performs well in a controlled setting may perform worse in practice if patients struggle to take it correctly. Oral semaglutide's 30-minute fasting window is a real-world barrier: no coffee, no glass of water, no other medications for half an hour after the dose.

For people who travel, work early shifts, have complex medication schedules, or simply find the rule hard to remember consistently, that window means missed doses and reduced absorption. Both orforglipron and aleniglipron solve this by design. The molecule survives digestion without help, so there is no window to manage.

This does not make aleniglipron better than oral semaglutide today. Oral semaglutide is approved and available. Aleniglipron is not. But it is a design choice that matters for the 2029 competitive landscape if Phase 3 holds up.

Where aleniglipron stands today

Structure Therapeutics is a small company by pharmaceutical standards. Eli Lilly, which makes orforglipron, is not. That size difference affects trial speed, enrollment capacity, manufacturing scale, and what happens when results come back. Phase 3 success does not automatically translate to market access, especially against two established competitors with multibillion-dollar commercial operations.

That said, Phase 2 numbers this strong draw attention from larger partners. And if aleniglipron does reach Phase 3 completion with similar efficacy, the oral GLP-1 market will have three serious options instead of two.

For context on the broader pipeline of next-generation obesity drugs, including the triple-agonist retatrutide currently in Phase 3, see what is retatrutide.